A Study of the Safety and Effectiveness of Nivolumab for the Treatment of Advanced Non-Small Cell Lung Cancer

Overview

About this study

The purpose of this study is to determine whether nivolumab alone or in combination with standard of care therapies will provide clinical benefit  without unacceptable toxicity for the treatment of advanced non-small cell lung cancer patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Histologically confirmed locally advanced or stage IV Non-small cell lung cancer
  • Eastern Cooperative Oncology Group (ECOG) Performance status 0-2 
  • Tumor tissue sections must be available for biomarker evaluation

Exclusion Criteria

  • Untreated or active/progressing Central Nervous system  metastases
  • Active, known or suspected autoimmune disease 
  • Known history of testing positive for HIV or AIDS 
  • Active or chronic infection of hepatitis B virus or hepatitis C

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Yanyan Lou, M.D., Ph.D.

Closed for enrollment

Contact information:

Yanyan Lou M.D., Ph.D.

Lou.Yanyan@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20542551

Mayo Clinic Footer